Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GDUFA III: How Much Of A Fee Increase Can Industry Stomach?

Feb 04 2020

• By Derrick Gingery

User Fee Reauthorization Preview 2020 — Worries about the generic industry's health may weigh on user fee renewal talks. • Source: Pink Sheet Illustration

Related Content

Complex Generics May Need New Communications Options In GDUFA III

Nov 26 2019

FDA May Not Implement User Fee Workload Adjuster In PDUFA VI

Apr 02 2018

US FDA's Brexit: One Staffer Moving, But Impact Still May Loom Large

Jan 09 2019

GDUFA III May Rely Less On PDUFA As A Role Model

Jun 06 2019

US FDA Reports Millions In Unpaid GDUFA Program Fees

Oct 07 2019

ANDA Approval Records Will End As US FDA Mops Up Backlog

Dec 05 2019

Generic Industry Market Forces May Impact GDUFA III Talks

Mar 22 2019

Will GDUFA III Curtail Priority Assessments?

Sep 14 2018

US Drug Pricing Legislation Efforts Headed Toward Spring Renewal? A Look Ahead

Jan 02 2020

Unhappy With GDUFA II? Note It For GDUFA III, FDA Says

Nov 28 2017

Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign

Aug 28 2017

Generic Drug User Fees Will Jump More Than 50% In FY 2018

Oct 17 2016

Additional Topics

United States Generic Drugs Review Pathway User Fees Regulation Drug Review FDA BioPharmaceutical Pink Sheet Perspectives

More from Generics

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window